Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Following Cataract Surgery

Completed · Phase 3

Conditions studied: Cataract

In brief

The objective of this clinical study is to compare the safety and efficacy of Mapracorat Ophthalmic Suspension, 3% to vehicle for the treatment of postoperative inflammation and pain following cataract surgery.

Key facts

Study ID

NCT01230125

Run by

Bausch & Lomb Incorporated

People needed

311

Starts

2010-11-01

Expected to finish

2011-08-01

Last updated by the study team

2020-09-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants who are candidates for routine, uncomplicated cataract surgery
• Participants who, in the Investigator's opinion, have potential postoperative pinhole Snellen visual acuity (VA) of at least 20/200 in the study eye.
• Participants must be willing to wait to undergo cataract surgery on the fellow eye until after the study has been completed.

You may not qualify if…

• Participants who are expected to require concurrent ocular therapy (either eye) with nonsteroidal anti-inflammatory drugs (NSAIDs), mast cell stabilizers, antihistamines, or decongestants.
• Participants who are expected to require treatment with any systemic or ocular (either eye) corticosteroids or glucocorticoids.
• Participants who are expected to require concurrent ocular therapy with immunosuppressants (eg, Restasis).
• Participants who have known hypersensitivity or contraindication to the study drug(s) or their components.
• Participants participating in any drug or device clinical investigation within 30 days prior to entry into this study and/or during the period of study participation.

Where it is running

• Bausch & Lomb, Incorporated — Rochester, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.